AstraZeneca Long Term Debt 2010-2024 | AZN

AstraZeneca long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.
  • AstraZeneca long term debt for the quarter ending March 31, 2024 was $27.259B, a 1.27% increase year-over-year.
  • AstraZeneca long term debt for 2023 was $22.365B, a 2.61% decline from 2022.
  • AstraZeneca long term debt for 2022 was $22.965B, a 18.37% decline from 2021.
  • AstraZeneca long term debt for 2021 was $28.134B, a 60.72% increase from 2020.
AstraZeneca Annual Long Term Debt
(Millions of US $)
2023 $22,365
2022 $22,965
2021 $28,134
2020 $17,505
2019 $15,730
2018 $17,359
2017 $15,560
2016 $14,501
2015 $14,137
2014 $8,397
2013 $8,588
2012 $9,409
2011 $7,338
2010 $9,097
2009 $9,137
AstraZeneca Quarterly Long Term Debt
(Millions of US $)
2024-03-31 $27,259
2023-12-31 $22,365
2023-09-30 $22,225
2023-06-30 $24,329
2023-03-31 $26,916
2022-12-31 $22,965
2022-09-30 $23,013
2022-06-30 $26,461
2022-03-31 $28,081
2021-12-31 $28,134
2021-09-30 $28,206
2021-06-30 $24,109
2021-03-31 $17,410
2020-12-31 $17,505
2020-09-30 $18,271
2020-06-30 $15,150
2020-03-31 $15,634
2019-12-31 $15,730
2019-09-30 $17,218
2019-06-30 $17,355
2019-03-31 $17,320
2018-12-31 $17,359
2018-09-30 $18,422
2018-06-30 $15,452
2018-03-31 $15,684
2017-12-31 $15,560
2017-09-30 $16,911
2017-06-30 $16,792
2017-03-31 $14,563
2016-12-31 $14,501
2016-09-30 $14,744
2016-06-30 $16,519
2016-03-31 $14,144
2015-12-31 $14,137
2015-09-30 $8,276
2015-06-30 $8,303
2015-03-31 $8,270
2014-12-31 $8,397
2014-09-30 $7,527
2014-06-30 $7,574
2014-03-31 $7,553
2013-12-31 $8,588
2013-09-30 $8,566
2013-06-30 $8,506
2013-03-31 $9,320
2012-12-31 $9,409
2012-09-30 $9,347
2012-06-30 $7,310
2012-03-31 $7,377
2011-12-31 $7,338
2011-09-30 $7,394
2011-06-30 $9,210
2011-03-31 $9,159
2010-12-31 $9,097
2010-09-30 $9,231
2010-06-30 $9,043
2010-03-31 $9,055
2009-12-31 $9,137
2009-09-30 $10,290
2009-06-30 $10,163
2009-03-31 $10,006
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $245.493B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $763.337B 110.33
Novo Nordisk (NVO) Denmark $606.535B 46.61
Johnson & Johnson (JNJ) United States $363.986B 14.46
Merck (MRK) United States $331.190B 60.26
AbbVie (ABBV) United States $287.713B 14.87
Novartis AG (NVS) Switzerland $210.205B 14.90
Pfizer (PFE) United States $161.838B 20.11
Sanofi (SNY) $123.824B 11.68
Innoviva (INVA) United States $1.008B 7.08